Text Size

Can Airflow Limitation in Chronic Obstructive Pulmonary Disease (COPD) be Reversible by Drugs?

This study has been completed.
Sponsor:
Information provided by:
Baqiyatallah Medical Sciences University
ClinicalTrials.gov Identifier:
NCT01010178
First received: November 6, 2009
Last updated: NA
Last verified: November 2009
History: No changes posted
  Purpose

Critical combination of various approved drugs in management for patients suffering with COPD.


Condition Intervention Phase
Chronic Obstructive Pulmonary Disease
 Drug: Macrolid, Theophylline, Inhaler Corticosteroids
 Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Combination of Approved Drug in COPD

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Baqiyatallah Medical Sciences University:

Primary Outcome Measures:
  • 15% increasing in forced expiratory volume in 1 second [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

Enrollment: 64
Study Start Date: February 2008
Study Completion Date: July 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Macrolid, Theophylline, Corticosteroids
Approved drug in this setting
 Drug: Macrolid, Theophylline, Inhaler Corticosteroids
we have no permission to include them in detail because of privacy policy of mentioned journal for publication

  Eligibility

Ages Eligible for Study:   22 Years to 86 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • current or past smoker COPD

Exclusion Criteria:

  • history of significant occupational or other environmental exposures or a connective tissue disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01010178

Locations
Iran, Islamic Republic of
Research Center of Chemical Injuries, Baqiyatallah Medical Sciences University, Mollasadra St,
Tehran, Iran, Islamic Republic of, 19945-546
Sponsors and Collaborators
Baqiyatallah Medical Sciences University
  More Information

No publications provided

Responsible Party: Corresponding Author: Research Center of Chemical Injuries, Baqiyatallah Medical Sciences University
ClinicalTrials.gov Identifier: NCT01010178     History of Changes
Other Study ID Numbers: BMT-1388-2
Study First Received: November 6, 2009
Last Updated: November 6, 2009
Health Authority: Iran: Ministry of Health

Keywords provided by Baqiyatallah Medical Sciences University:
COPD
Macrolid
reversibility
 Theophylline
Corticosteroids
symptoms PFT

Additional relevant MeSH terms:
Lung Diseases
Respiration Disorders
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Respiratory Tract Diseases
Theophylline
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
 Physiological Effects of Drugs
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Vasodilator Agents
Cardiovascular Agents

ClinicalTrials.gov processed this record on May 23, 2013